# STERIS plc (STE) — Stock CV

STERIS plc is a $20.9B healthcare company. Revenue grew 8.4% over the last year, it keeps 13¢ of every dollar of sales as profit, and its net debt equals ~1.8 years of free cash flow. It trades at 26.0× earnings — near the lowest of its own history.

> Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world.

## Identity

- **Ticker**: STE
- **Sector**: Healthcare
- **Industry**: Orthopedic, Prosthetic & Surgical Appliances & Supplies
- **Headquarters**: DUBLIN, L2
- **Employees**: 17 937
- **Website**: https://www.steris.com
- **Market cap**: $20.9B
- **Last price**: $214.40
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $6.04B
- **Net income**: $805M
- **Free cash flow**: $926M
- **Net debt**: $1.65B
- **P/E**: 26.0
- **Revenue growth (YoY)**: 8.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 77 |
| Growth | 74 |
| Profitability | 64 |
| Health | 80 |
| Quality | 100 |
| Moat | 57 |

## Qualifications (beginner checklist) — 10 of 11 passed

- [x] Revenue growing — +8.4% YoY
- [x] Profitable — $805M TTM
- [x] Profit growing — +95.1% YoY
- [x] Generates cash — $926M TTM
- [x] Debt under control — ~1.8y of cash flow to repay
- [x] Established company — $20.9B market cap
- [ ] Not printing shares — +30.2% shares over ~5y
- [x] Proven track record — 8/8 profitable years
- [x] Financially stable — Altman Z 4.3 — safe
- [x] Pays a dividend — yield 1.18%
- [x] Valuation not extreme — P/E 26.0

## Experience (career milestones)

- **FY2026** — Best year on record: $782M net income
- **2021** — Steris acquired Cantel Medical Corporation a provider of infection prevention products and services to…
- **2020** — Steris acquired Key Surgical, a leading global provider of sterile processing, operating room
- **FY2019** — Profitable every year on record: 8 consecutive profitable years in our data
- **FY2019** — Revenue already above $1B: $2.78B in first reported year
- **FY2019** — Positive free cash flow every year since: 8-year streak
- **2014** — Steris executed a tax inversion from the United States to the United Kingdom, via an offer made to…
- **2014** — The tax inversion was notable as it was the first US inversion post the new rules introduced by the Obama…
- **2012** — Steris acquired US Endoscopy for $270 million
- **1985** — Steris was founded in August 1985 in Ohio, under the name "Innovative Medical Technologies"

## Strengths

- High gross margin (44.4%)
- Strong cash conversion — FCF is 15.3% of revenue
- Could repay net debt from ~1.7 years of free cash flow
- Interest covered 21.6× by operating earnings
- Piotroski F-Score 8/9 — fundamentally strong checklist

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2022 | $4.59B | $244M | $397M |
| FY2023 | $4.54B | $107M | $395M |
| FY2024 | $5.14B | $378M | $613M |
| FY2025 | $5.46B | $615M | $778M |
| FY2026 | $5.94B | $782M | $972M |

---

Source: https://stockcv.com/STE — derived from company filings; may be delayed or incomplete. Information, not investment advice.